Optimization of arylindenopyrimidines as potent adenosine A2A/A1 antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 9, 2010, Pages 2868-2871

  Shook, Brian C ^a   Rassnick, Stefanie ^a   Chakravarty, Devraj ^a   Wallace, Nathaniel ^a   Ault, Mark ^a   Crooke, Jeffrey ^a   Barbay, J Kent ^a   Wang, Aihua ^a   Leonard, Kristi ^a   Powell, Mark T ^a   Alford, Vernon ^a   Hall, Daniel ^a   Rupert, Kenneth C ^a   Heintzelman, Geoffrey R ^a   Hansen, Kristen ^a   Bullington, James L ^a   Scannevin, Robert H ^a   Carroll, Karen ^a   Lampron, Lisa ^a   Westover, Lori ^a   Russell, Ronald ^a   Branum, Shawn ^a   Wells, Kenneth ^a   Damon, Sandra ^a   Youells, Scott ^a   Beauchamp, Derek ^a   Li, Xun ^a   Rhodes, Kenneth ^a   Jackson, Paul F ^a   more..

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

A1 Antagonist; A2A Antagonist; Adenosine antagonists; Dopamine; Mouse catalepsy; Parkinson's disease

Indexed keywords

ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR ANTAGONIST; AMIDE; AMINE; ETHER DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; REACTION OPTIMIZATION;

ANIMALS; CATALEPSY; DISEASE MODELS, ANIMAL; MICE; NEUROTRANSMITTER AGENTS; PYRIMIDINES; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2A; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77950936818     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.03.024     Document Type: Article

References (23)

1. Fredholm B.B., Abbraccio M.P., Burnstock G., Daly J.W., Harden T.K., Jacobson K.A., Leff P., and Williams M. Pharmacol. Rev. 46 (1994) 143
2. Fredholm B.B., Cunha R.A., and Svenningsson P. Curr. Top. Med. Chem. 3 (2002) 1349
3. Augood S.J., and Emson P.C. Mol. Brain Res. 22 (1994) 204
4. Dunwiddie T.V., and Masino S.A. Annu. Rev. Neurosci. 24 (2001) 31
5. Klaasse K.C., Ijzerman A.P., Grip W.J., and Beukers M. Purinergic Signal. 4 (2008) 21
6. Simola N., Morelli M., and Pinna A. Curr. Pharm. Des. 14 (2008) 1475
7. Palmer T.M., and Stiles G.L. Neuropharmacology 34 (1995) 683
8. Shook B.C., Rassnick S., Hall D., Rupert K.C., Heintzelman G.R., Hansen K., Chakravarty D., Bullington J.L., Scannevin R.H., Magliaro B., Westover L., Carroll K., Lampron L., Russell R., Branum S., Wells K., Damon S., Youells S., Li X., Osbourne M., Demarest K., Tang Y., Rhodes K., and Jackson P.F. Bioorg. Med. Chem. Lett. 20 (2010) 2864
9. Heintzelman, G. R.; Bullington, J. L.; Rupert, K. C. WO Patent 2005042500.
10. Muller C.E., and Scior T. Pharm. Acta Helv. 68 (1993) 77
11. DeNinno M.P. Annu. Rep. Med. Chem. 33 (1998) 111
12. Pires V.A., Pamplona F.A., Pandolfon P., Fernandes D., Prediger R.D.S., and Takahashi R.N. Behav. Pharmacol. 20 (2009) 134
13. Davidson D.A., and Weidley E. Life Science 18 (1976) 1279-1284
14. Shook, B. C.; Jackson, P. F. WO Patent 2009055548.
15. Shook, B. C.; Jackson, P. F. WO Patent 2009055308.
16. Griffith W.P., Jolliffe J.M., Ley S.V., Springhorn K.F., and Tiffin P.D. Synth. Commun. 22 (1992) 1967
17. Zarrindast M.R., Modabber M., and Sabetkasai M. Psychopharamcology 113 (1993) 257
18. Schwarzschild M.A., Agnati L., Fuxe K., Chen J.F., and Morelli M. Trends Neurosci. 29 (2006) 647
19. Kuck D., Paisdor B., and Gruetzmacher H.F. Chem. Ber. 120 (1987) 589
20. Bullington J.L., Cameron J.C., Davis J.E., Dodd J.H., Harris C.A., Henry J.R., Lee Pellegrino-Gensey J., Rupert K.C., and Siekierka J.J. Bioorg. Med. Chem. Lett. 8 (1998) 2489
21. Walters, M. E.; Kolonko, R. P.; Wehmeyer, R. M. U.S. Patent 1996-5545760.
22. Bernard A.M., Ghiani M.R., Piras P.P., and Rivoldini A. Synthesis (1989) 287
23. Vicker N., Burgess L., Chuckowree I.S., Dodd R., Folkes A.J., Hardick D.J., Hancox T.C., Miller W., Milton J., Sohal S., Wang S., Wren S.P., Charlton P.A., Dangerfield W., Liddle C., Mistry P., Stewart A.J., and Denny W.A. J. Med. Chem. 45 (2002) 721